Completed PHASE2 INTERVENTIONAL NCT00280787

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung

Sponsor: Amgen

Conditions Non Small Cell Lung Cancer

Interventions CPT-11 Carboplatin Conformal radiotherapy Paclitaxel Pegfilgrastim

Updated 6 times since 2017 Last updated: Feb 1, 2013 Started: Nov 30, 2003 Primary completion: Jan 31, 2006 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00280787, this PHASE2 trial focuses on Non Small Cell Lung Cancer and remains completed. Sponsored by Amgen, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
AstraZeneca
UNC Lineberger Comprehensive Cancer Center

Data source: UNC Lineberger Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chapel Hill, United States